Babak Bedayat, MD
Interventional Pain Medicine · Culpeper, VANPI 1083896955
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,900 of the $6,191 with a category attached, or 63.0%. 33 manufacturers reported payments, led by Medtronic at 37.4% of the total.
Across 202 payments — averaging $30.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$1K
- IBSA Pharma Inc.$624
- Lilly USA, LLC$271
- Biohaven Pharmaceutical Holding Company Ltd.$228
- Nevro Corp.$202
- plus $1K from 27 others
What the payments were for
- Travel & lodging$2,29137%
- Food & beverage$3,90063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 26 | $2,313 |
| Boston Scientific | 14 | $1,303 |
| IBSA Pharma Inc. | 43 | $624 |
| Lilly USA, LLC | 13 | $271 |
| Biohaven Pharmaceutical Holding Company Ltd. | 24 | $228 |
| Nevro Corp. | 9 | $202 |
| Pfizer | 17 | $157 |
| Biogen | 6 | $126 |
| Corcept Therapeutics | 5 | $108 |
| Amgen | 4 | $87 |
| Avanos Medical | 4 | $85 |
| Novo Nordisk | 4 | $83 |
| Abbott | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 4 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $45 |
| Boehringer Ingelheim | 2 | $43 |
| AbbVie | 2 | $37 |
| Bayer | 1 | $30 |
| Watermark Medical, Inc. | 1 | $25 |
| Exact Sciences | 1 | $24 |
| Sanofi | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Vertex | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Electronic Waveform Lab, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADAPTIVESTIM$1,101
- WaveWriter Alpha Prime 16$833
- INTELLIS$386
- INCEPTIV$353
- GENERAL PAIN MANAGEMENT$269
How this compares
$6,191 in reported general payments places this provider in the 60th percentile of 52 interventional pain medicine providers in Virginia.
See all interventional pain medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 12 | $11,179 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 451 | $7,691 |
| Tizanidine Hcl | 874 | $6,675 |
| Gabapentin | 422 | $5,427 |
| Duloxetine Hcl | 467 | $4,577 |
| Oxycodone Hcl | 279 | $4,310 |
| OxycontinOxycodone Hcl | 14 | $4,106 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 143 | $2,424 |
| Tramadol Hcl | 245 | $1,655 |
| Lidocaine | 28 | $1,070 |
| Pregabalin | 71 | $1,017 |
| Morphine Sulfate ErMorphine Sulfate | 55 | $775 |
| Celecoxib | 15 | $771 |
| Methadone Hcl | 51 | $697 |
| Diclofenac Sodium | 44 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $45 | $11,17912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 52 interventional pain medicine providers in Virginia.
Other interventional pain medicine in Culpeper
- Daniel HalpertCulpeper$796
- Ketan PatelHaymarket$133K
- Che TorryNewport News$48K
- Niteesh BhararaReston$25K
- Sassan HassassianManassas$24K
- Raj SurejaNewport News$23K
- Benjamin SeemanRichmond$21K
- Alok GopalWinchester$16K
- Jacob LeeWinchester$14K
- Yaoming GuRichmond$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.